Paolo Paoletti will head up GSK Oncology, which consolidates small discovery units and a highly specialised drug development group to create an oncology R&D center within the company.
Related Articles:
GSK shakes up R&D
GSK plant closure begins 5,000 job cuts
Behind the scenes of GSK's overhaul
The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!
Comments